Previous 10 | Next 10 |
SANTA MONICA, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air on The...
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- NeurMedix, LLC, a San Diego based privately held clinical stage pharmaceutical company announced that it has received authorization from the U.S. Food and Drug Administration’s (FDA) Office of Neuroscience, Division of Neurology I, to init...
BioVie (BIVI) files for a mixed shelf offering of up to $100M in securities.The filing does not necessarily indicate that a sale has begun, or will occur in the futureSEC Form S-3BioVie shares closed today's session down 7.3%, but the stock's been on a big run higher, rising more th...
B. Riley Securities initiates coverage for a mid-cap clinical-stage company, BioVie ([[BIVI]] +23.2%) with a Buy rating and price target of $47 (26% upside).Analyst Mayank Mamtani added, "We believe that the company is developing innovative drug therapies for liver disease, which is...
Click here to read the previous top NASDAQ pharma stocks article. 2020 wasn’t without challenges for the pharmaceutical market, which like other sectors is bound to face lasting impacts from the COVID-19 pandemic. That being said, the major underlying drivers for ...
SANTA MONICA, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air o...
SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it will participate in the B. Riley Securities’ Liver Disease Therapeu...
Insider buying decreased once again last week. Notable Insider Buys: Gossamer Bio, Inc., Selecta Biosciences, Inc., Citigroup Inc., Loop Industries, Inc., and BioVie Inc. Notable Insider Sells: Okta, Inc., Paycom Software, Inc., Apple Inc., salesforce.com, inc., and Workday, Inc. ...
Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead. Several companies could join the IPO calendar early in the week, including McAfee and Datto Holding. Street research is expe...
SANTA MONICA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it has closed its previously announced underwritten public offering of Class...
News, Short Squeeze, Breakout and More Instantly...
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Ti...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomb...